Niagen Bioscience (NAGE) Income from Non-Controlling Interests (2019 - 2020)
Niagen Bioscience (NAGE) posted quarterly Income from Non-Controlling Interests of $3000.0 for Q2 2020, down 70.0% year-over-year from $10000.0 in Q3 2019, and down 70.0% quarter-over-quarter from $10000.0 in Q2 2019.
Powered by 
Analysis
Niagen Bioscience (NAGE) Income from Non-Controlling Interests (2019 - 2020) Analysis & Trends
Niagen Bioscience (NAGE) has reported Income from Non-Controlling Interests for 2 consecutive years, with $3000.0 the latest figure, recorded in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | - |